Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...
Director nominees with CEO experience have long featured in Board slates put forward by activist investors. Those candidates were typically from outs ...
Jeffrey Smith’s Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund’s new buys during the fourth quarter ...
Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Kenvue shares were more or less flat after activist investment firm Starboard Value launched a ... could generate problems similar to those Pfizer experienced on the stock market after its ...
That Pfizer’s turnaround is already well underway is reflected by the fact that activist investor Starboard Value, led by Jeffrey Smith, wisely chose not to nominate any dissident directors to ...
Investing.com -- Hedge fund Starboard Value has nominated four directors for positions on the board of consumer products company Kenvue (NYSE:KVUE), according to a regulatory filing revealed on ...
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing transformative changes.’ ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...